Sign in

Matthew Keeler

MedTech Analyst at Credit Suisse Asset Management Llc/ny

Matthew Keeler is a MedTech Analyst at Credit Suisse, specializing in medical technology equity research with a focus on companies such as Leap Therapeutics and Endologix. He has participated in high-profile industry conferences and earnings calls, providing targeted insights for institutional investors, although specific performance metrics and ranking data are not publicly disclosed. Keeler's career trajectory includes prior senior analyst roles at BNY Mellon Wealth Management, where he was a Senior Healthcare Analyst and previously served as Vice President. He holds professional credentials verified by FINRA, with active securities registrations confirming his authority in equity research analysis.

Matthew Keeler's questions to LEAP THERAPEUTICS (LPTX) leadership

Question · Q1 2015

Matthew Keeler of Credit Suisse asked for clarification on the upcoming VLU trial futility analysis and inquired about physician feedback on CureXcell's mechanism of action data presented at the Symposium for Advanced Wound Care (SAWC).

Answer

President and CEO Nissim Mashiach explained the futility analysis has three potential outcomes based on probability of success, with the company anticipating a recommendation to continue the trial. Chief Medical Officer Mike Molyneaux added that feedback at SAWC was 'extremely positive,' with physicians excited by the robust and differentiated data presented.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts